Jacob L van Dam

12PUBLICATIONS
67CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jan 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.

Ruth A L Willems, Aniek E van Diepen, Esther N Dekker

|May 06, 2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study.

Thomas F Stoop, Y H Andrew Wu, Atsushi Oba

|Feb 05, 2024
Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.

Esther N Dekker, Jacob L van Dam, Quisette P Janssen

|Jul 13, 2023
Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.

Deesje Doppenberg, Jacob L van Dam, Youngmin Han

|Jul 18, 2022
Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study.

Fleur van der Sijde, Jacob L van Dam, Bas Groot Koerkamp

|Feb 14, 2022
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.

Quisette P Janssen, Jacob L van Dam, Deesje Doppenberg

Pageof 2

Frequent Collaborators

9 joint publications

Bas Groot Koerkamp

8 joint publications

Marc G Besselink

4 joint publications

Olivier R Busch

4 joint publications

Judith de Vos-Geelen